您的位置：山东大学 -> 科技期刊社 -> 《山东大学学报（医学版）》

山东大学学报（医学版） ›› 2017, Vol. 55 ›› Issue (11): 47-53.doi: 10.6040/j.issn.1671-7554.0.2016.133

• 临床医学 • 上一篇    下一篇

PADI2与人多种肿瘤的遗传易感性的关系

李昌1,2,张倩3,马芳4,解奇2,常晓天2   

  1. 1. 山东省滕州市中心人民医院病理科, 山东 滕州 277500;2. 山东大学附属千佛山医院医学研究中心, 山东 济南 250014;3. 北大医疗鲁中医院检验科, 山东 淄博 255400;4. 山东省创新制药有限公司, 山东 济南 250101
  • 收稿日期:2016-02-08 出版日期:2017-11-10 发布日期:2017-11-10
  • 通讯作者: 常晓天. E-mail:changxt@126.com E-mail:changxt@126.com
  • 基金资助:
    山东省卫生科技发展计划(2014GSF118135,2014WS0021,2016WS0629);国家自然科学基金面上项目(81171990)

Relationship between PADI2 and genetic susceptibility in various human tumors

LI Chang1,2, ZHANG Qian3, MA Fang4, XIE Qi2, CHANG Xiaotian2   

  1. 1. Pathological Department, Tengzhou Central People's Hosptial, Tengzhou 277500, Shandong, China;
    2. Medical Research Center, Qianfoshan Hospital Affiliated to Shandong University, Jinan 250014, Shandong, China;
    3. Clinical Laboratory, PKU Care Luzhong Hospital, Zibo 255400, Shandong, China;
    4. Shandong Chuangxin Biological Technology Company, Jinan 250101, Shandong, China
  • Received:2016-02-08 Online:2017-11-10 Published:2017-11-10

PDF (PC)

527

摘要： 目的 探讨肽基精氨酸脱亚氨酶(PAD)家族成员之一PADI2基因对肿瘤的遗传易感性及其在肿瘤组织和患者血液中的表达情况。 方法 采用Sequenom MassARRAY基因分型技术分析PADI2编码基因上的标签单核苷酸多态性(SNP)rs2746533、rs79395834、rs2076616和rs10788656位点与乳腺癌、宫颈癌、食管癌、胃癌、肝癌、肺癌、卵巢癌和直肠癌患者是否存在遗传易感性。采用免疫组化技术检测PADI2在乳腺癌、宫颈癌、食管癌、胃癌、肝癌、肺癌、卵巢癌、结肠癌、直肠癌和甲状腺癌组织内的表达。采用ELISA技术检测PADI2在乳腺癌、宫颈癌、食管癌、胃癌、肝癌、肺癌、卵巢癌、直肠癌患者外周血中的表达水平。 结果 Sequenom MassARRAY基因分型实验显示,PADI2基因的rs2746533、rs2076616、rs10788656位点与乳腺癌、宫颈癌、胃癌、肺癌、直肠癌发病明显相关。免疫组化实验发现,PADI2在95%的乳腺浸润性导管癌、97.5%的结肠腺癌、88%的食管癌、92.5%的肺癌和90%甲状腺乳头状癌组织高表达。除了一些间充质样细胞和内皮细胞外,PADI2在正常宫颈组织、肺组织、卵巢组织或甲状腺组织中不表达,在乳腺、结肠、食管、胃、肝和直肠正常组织的上皮细胞中低表达。ELISA实验发现PADI2在86%的肝癌、38%宫颈癌和32%胃癌患者外周血中表达水平上升2倍以上。 结论 PADI2与多种肿瘤遗传易感性相关并在多种肿瘤组织和血液中高表达,提示PADI2可能与这些肿瘤的发病有关。

关键词: 易感基因, 肿瘤, 基因分型, 肽基精氨酸脱亚氨酶2, 基因表达

Abstract: Objective To investigate the expression of peptidyl demitasse isoform 2(PADI2), a PAD family member, in various tumor tissues and the blood of patients and to investigate the correlation between PADI2 encoding gene and tumor risks. Methods Sequenom MassARRAY genotyping assay was used to determine the potential association of tag single nucleotide polymorphisms(SNPs)including rs2746533, rs79395834, rs2076616, rs10788656 in PADI2 gene to various tumor types(breast cancer, cervical cancer, esophageal cancer, stomach cancer, liver cancer, lung cancer, ovarian cancer, colon cancer, rectal cancer and thyroid cancer). Immunohistochemistry was used to determine the PADI2 expression and location in tumor tissues. ELISA was used to detect the PADI2 level in blood of the tumor 山 东 大 学 学 报 (医 学 版)55卷11期 -李昌,等.PADI2与人多种肿瘤的遗传易感性的关系 \=-patients. Results The case-control analysis showed a significant association between rs2746533, rs2076616 and rs10788656 and breast cancer, cervical carcinoma, esophageal carcinoma, gastric carcinoma, lung cancer and rectal carcinoma risks. PADI2 expression significantly increased in 95% of the patients with breast invasive ductal carcinoma, 97.5% of the patients with colonal adenocarcinoma, 88% of the patients with esophageal squamous cell carcinoma, and 92.5% of the patients with lung cancers and 90% of thyroid carcinoma papillary carcinoma samples, but not in the corresponding healthy tissues, except that in some mesenchymal cells and endothelial cells. A two-fold increase in PADI2 expression was detected in the blood of 86% of patients with liver cancer, 38% of patients with cervical carcinoma and 32% of patients with gastric carcinoma. Conclusion PADI2 has genetic susceptibility to many kinds of tumor and is highly expressed in various tumor tissues and blood of the patients. The finding suggests an important role for PADI2 in tumorigenesis.

Key words: Susceptibility gene, Tumor, Gene expression, Peptidyl deiminase isoform 2, Genotype

中图分类号: 

  • R394.5
[1] Wesche J, Kuhn S, Kessler BM, et al. Protein arginine methylation: a prominent modification and its demethylation[J]. Cell Mol Life Sci, 2017, 74(18): 3305-3315.
[2] Tu R, Grover HM, Kotra LP. Peptidyl arginine deiminases and neurodegenerative diseases[J]. Curr Med Chem, 2016, 23(2):104-114.
[3] Mohanan S, Cherrington BD, Horibata S, et al. Potential role of peptidylarginine deiminase enzymes and protein citrullination in cancer pathogenesis[J]. Biochem Res Int, 2012: 895343. doi:10.1155/2012/895343.
[4] McElwee JL, Mohanan S, Griffith OL, et al. Identification of PADI2 as a potential breast cancer biomarker and therapeutic target[J]. BMC Cancer, 2012, 12: 500. doi: 10.1186/1471-2407-12-500.
[5] Cherrington BD, Morency E, Struble AM, et al. Potential role for peptidylarginine deiminase 2(PAD2)in citrullination of canine mammary epithelial cell histones[J]. PLoS One, 2010, 5(7): e11768. doi: 10.1371/journal.pone.0011768.
[6] Cherrington BD, Mohanan S, Diep AN, et al. Comparative analysis of peptidylarginine deiminase-2 expression in canine, feline and human mammary tumours[J]. J Comp Pathol, 2012, 147(2-3): 139-146.
[7] McElwee JL, Mohanan S, Horibata S, et al. PAD2 overexpression in transgenic mice promotes spontaneous skin neoplasia[J]. Cancer Res, 2014, 74(21):6306-6317.
[8] Briggs DJ, Skeeles JK. An enzyme-linked immunosorbent assay for detecting antibodies to Pasteurella multocida in chickens[J]. Avian Dis, 1984, 28(1):208-215.
[9] Chang X, Xia Y, Pan J, et al. PADI2 is significantly associated with rheumatoid arthritis[J]. PLoS One, 2013, 8(12): e81259. doi: 10.1371/journal.pone.0081259.
[10] Shangkuan WC, Lin HC, Chang YT, et al. Risk analysis of colorectal cancer incidence by gene expression analysis[J]. PeerJ, 2017, 5: e3003. doi: 10.7717/peerj.3003.
[11] Cherrington BD, Zhang X, McElwee JL, et al. Potential role for PAD2 in gene regulation in breast cancer cells[J]. PLoS One, 2012, 7(7): e41242. doi: 10.1371/journal.pone.0041242.
[12] Bhattacharya SK, Crabb JS, Bonilha VL, et al. Proteomics implicates peptidyl arginine deiminase 2 and optic nerve citrullination in glaucoma pathogenesis[J]. Invest Ophthalmol Vis Sci, 2006, 47(6):2508-2514.
[13] McElwee JL, Mohanan S, Horibata S, et al. PAD2 overexpression in transgenic mice promotes spontaneous skin neoplasia[J]. Cancer Res, 2014, 74(21):6306-6317.
[14] Cantarino N, Musulen E, Valero V, et al. Downregulation of the deiminase PADI2 is an early event in colorectal carcinogenesis and indicates poor prognosis[J]. Mol Cancer Res, 2016, 14(9):841-848.
[15] Wang H, Xu B, Zhang X, et al. PADI2 gene confers susceptibility to breast cancer and plays tumorigenic role via ACSL4, BINC3 and CA9 signaling[J]. Cancer Cell Int, 2016, 16:61. doi: 10.1186/s12935-016-0335-0.
[16] Jiang Z, Cui Y, Wang L, et al. Investigating citrullinated proteins in tumour cell lines[J]. World J Surg Oncol, 2013, 11: 260. doi: 10.1186/1477-7819-11-260.
[17] Chang X, Fang K. PADI4 and tumourigenesis[J]. Cancer Cell Int, 2010, 10:7. doi: 10.1186/1475-2867-10-7.
[18] Slack JL, Causey CP, Thompson PR. Protein arginine deiminase 4: a target for an epigenetic cancer therapy[J]. Cell Mol Life Sci, 2011, 68(4):709-720.
[19] Ying S, Dong S, Kawada A, et al. Transcriptional regulation of peptidylarginine deiminase expression in human keratinocytes[J]. J Dermatol Sci, 2009, 53(1): 2-9.
[1] 王伟 王沂峰 张岭梅 林琼燕 黄菊. 人卵巢癌OVCAR3细胞系中侧群细胞的分离及其成瘤性、侵袭性的实验研究[J]. 山东大学学报(医学版), 2209, 47(6): 8-11.
[2] 张士宝 刘庆勇 阮喜云 陈杰 张建军 李宗武 杨广笑 王全颖. NT4-SAC-HA2-TAT融合基因表达载体的构建及鉴定[J]. 山东大学学报(医学版), 2209, 47(6): 15-19.
[3] 李波波 李道堂 刘曙光 王兴武. 食管癌患者血清中DKK-1的表达[J]. 山东大学学报(医学版), 2209, 47(6): 58-61.
[4] 鹿向东 杨伟 徐广明 曲元明. 脑膜瘤中PPAR-γ的表达及曲格列酮对脑膜瘤培养细胞生长的影响[J]. 山东大学学报(医学版), 2209, 47(6): 65-.
[5] 黄方 康瑞 吴春林. VEGFC、NF-κBp65及Survivin在鼻咽癌中的表达及临床意义[J]. 山东大学学报(医学版), 2209, 47(6): 83-.
[6] 林明霞,刘桂斌,马燕花,连曌昱,任洋洋. ATP酶铜转运蛋白α介导的铜死亡途径及在肿瘤治疗中的价值[J]. 山东大学学报 (医学版), 2026, 64(4): 117-124.
[7] 邹宇锦,万熠,纪振冰,梁西昌. 促骨再生-抗肿瘤双功能钛合金植入体的生物实验研究[J]. 山东大学学报 (医学版), 2026, 64(2): 50-65.
[8] 张秋萍,朱慧志,吕川,夏咏琪,张秀. 基于生物信息学分析鉴定哮喘潜在的关键自噬和铁死亡相关基因[J]. 山东大学学报 (医学版), 2026, 64(1): 74-87.
[9] 李雪凯,孙淋涵,刘端瑞,倪阳. 乳酸化修饰在肿瘤炎癌进程中的功能与机制研究进展[J]. 山东大学学报 (医学版), 2025, 63(9): 65-76.
[10] 王雪梅,杨豪,宋洋,程世超,张婷婷,王艳春. 抗糖尿病药物与女性恶性肿瘤的因果关联:一项两样本孟德尔随机化分析[J]. 山东大学学报 (医学版), 2025, 63(6): 67-77.
[11] 赵汉卿,周新睿,李子建,唐兴. 循环肿瘤细胞联合血清学检测在非小细胞肺癌中的应用[J]. 山东大学学报 (医学版), 2025, 63(5): 79-85.
[12] 黄馨,王梦雪,付书璠,张琦悦,徐力. 代谢综合征及其组分与消化系统恶性肿瘤的因果关联:两样本孟德尔随机化研究[J]. 山东大学学报 (医学版), 2025, 63(5): 86-94.
[13] 杜雪,李春霞,刘云霞,张涛. 基于MFPC-Cox的结直肠癌患者预后动态预测模型[J]. 山东大学学报 (医学版), 2025, 63(5): 101-110.
[14] 王宝炫,焦杰,张厚君,刘奇,于冠英. 衰弱与肌少症评估在胃肠道肿瘤术后结局预测中的应用与展望[J]. 山东大学学报 (医学版), 2025, 63(4): 51-58.
[15] 宋雅雯,郭联涛,孔德光,孙圣荣. VTCN1导致HR+乳腺癌预后不良及内分泌治疗耐药[J]. 山东大学学报 (医学版), 2025, 63(1): 43-59.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
版权所有 © 2018 《山东大学学报(医学版)》编辑部　
地址:山东大学科技期刊社（济南市历城区山大南路27号山东大学中心校区明德楼B座721室） 电话: 0531-88366918 E-mail: xbyxb@sdu.edu.cn
本系统由北京玛格泰克科技发展有限公司设计开发